title: Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.
abstract: Donor lymphocyte infusions (DLIs) are an effective treatment for relapsed Chronic myeloid leukemia (CML) after allogeneic transplantation but are limited by the occurrence of GVHD. CD8+ T lymphocytes are involved in the pathogenesis of GVHD but may not be essential for the graft-versus-leukemia (GVL) effect in CML. We have treated 26 CML patients with posttransplantation relapse with CD8-depleted DLI. Thirteen of 15 patients (87%) who relapsed in early-phase CML achieved complete cytogenetic response, but only 1 of 11 who relapsed in advanced-phase disease achieved complete response. Acute GVHD occurred in 2 patients (8%), and extensive chronic GVHD occurred in 2 patients (11%). Treatment-related mortality was 11.5%. Responses were durable; with a median follow-up of 4.2 years (1-7.5 years), only 1 responding patient relapsed (7%). CD8-depleted DLI was equally effective and safe after unrelated donor transplants and sibling transplants. Cytogenetic clonal evolution at the time of DLI was not predictive of treatment failure unless associated with hematologic criteria for disease acceleration. CD8 depletion is an effective method to separate GVL from GVHD for posttransplantation relapsed CML. This strategy is associated with durable complete remissions and a low rate of complications and therefore merits further investigation in larger-scale comparative trials.
authors.affiliation: Department of Blood and Bone Marrow Transplantation, University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: A
authors.initials: A
authors.lastname: Shimoni
authors.forename: J A
authors.initials: JA
authors.lastname: Gajewski
authors.forename: M
authors.initials: M
authors.lastname: Donato
authors.forename: T
authors.initials: T
authors.lastname: Martin
authors.forename: S
authors.initials: S
authors.lastname: O'Brien
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
authors.forename: A
authors.initials: A
authors.lastname: Cohen
authors.forename: M
authors.initials: M
authors.lastname: Korbling
authors.forename: R
authors.initials: R
authors.lastname: Champlin
authors.forename: S
authors.initials: S
authors.lastname: Giralt
mesh_terms: D000328:Adult; D016827:CD8 Antigens / Q000032:analysis*; D002469:Cell Separation; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000276:immunology; D020544:Graft vs Leukemia Effect / Q000276:immunology; D006801:Humans; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000401:mortality / Q000628:therapy*; D016131:Lymphocyte Subsets; D017710:Lymphocyte Transfusion / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000009:adverse effects; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016827:CD8 Antigens